

2016


2017

2018

2019

2020

2021



WHO recommends DTG & EFV 400 mg as Alternative 1st Line Regimens  
Jan 24

USFDA Approves TAF/FTC  
Apr 4

USFDA Tentative Approval Generic DTG 50 mg  
Sep 22

First SRA/PQ Filings Generic DTG/TDF/3TC  
Mar 30

First SRA/PQ Filings Generic TAF/FTC, TAF/DTG/FTC & DRV/r  
Jun 30

First SRA/PQ Filings Generic DTG/TDF/3TC  
Mar 30

First SRA/PQ Filings Generic DTG/DRV/r  
Jan 1

**REGULATORY**

**KEY**

- ▶ Trial Initiation & End
- ◆ Enrolment Ends
- ◆ Week 48 Data Available
- ◆ Final Data Available
- ◆ Sub-study Related
- ◆ Related Study Ends

**TRIALS**

- ADVANCE** DTG/TAF/FTC : DTG/TDF/FTC : EFV/TDF/FTC
- NAMSAL** DTG/TDF/3TC : EFV 400/TDF/3TC
- DoIPHIN2** DTG/TDF/FTC : EFV 600/TDF/FTC
- SSAT062** EFV 600 > EFV 400 > EFV 400 + INH + RIF
- WRHI052** LPV/r : DRV/r
- D<sup>2</sup>EFT** DRV 800/r + 2-3 N(t)RTIs : DTG + DRV 400/r

**DRUG ABBREVIATIONS**

- DTG** dolutegravir
- TDF** tenofovir disoproxil fumarate
- TAF** tenofovir alafenamide fumarate
- EFV** efavirenz
- FTC** emtricitabine
- 3TC** lamivudine
- RIF** rifampicin
- INH** isoniazid
- LPV/r** lopinavir + ritonavir
- DRV/r** darunavir + ritonavir

**ART OPTIMIZATION PROGRAMME TIMELINES**



USAID FROM THE AMERICAN PEOPLE



PEPFAR

